By attenuating the translation of key mRNA targets, ZFP36 RNA binding proteins restrain the expansion and effector activity of T cells.

Temporally regulated RNA-binding proteins orchestrate RNA splicing to drive myogenesis.

Inactivation of a multifunctional RNA-binding protein can lead to the acquisition of pro-metastatic phenotypes, possibly by stabilizing large-scale transcriptomic changes that provide a selective advantage during cancer progression.

Messenger RNA degradation alters protein trafficking to control transcription.

A genetic screening approach identifies RNA binding proteins that enhance or inhibit the accumulation of CD138+ plasma cells in vitro, and chimeric mouse models demonstrate that YTHDF2 promotes the accumulation of antibody secreting cells in vivo.

The RNA-binding protein Elavl1 directly binds to and stabilizes a single gene product—Draxin mRNA—to prevent premature delamination and maintain specification in cranial neural crest.

Tissue-specific transcription factors, such as basic motif leucine zipper protein NRL, interact with a plethora of RNA-binding proteins to perform pleiotropic functions during distinct steps of transcription process to generate quantitatively precise patterns of gene expression in neuronal cells.

Zfp106 functions as an RNA binding protein, binds directly to GGGGCC RNA repeats, is required in motor neurons to prevent ALS-like neurodegeneration in mice, and can suppress neurotoxicity in an established fly model of ALS.

The disease-associated RNA binding protein Nab2 is required to inhibit m⁶A RNA methylation in female Drosophila neuronal tissue and controls key splicing events such as sex-specific splicing of the Sex-lethal RNA.

A family of RNA binding proteins that diverged 200 million years ago have parallel roles in protecting the transcriptomic integrity of ultra-long exons within their respective cell types.